Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics

Thapa, P.Ranade, R.Ostwal, V.Shrikhande, S. V.Goel, M.Basu, Sandip2017-04-032017-04-032016Nuclear Medicine Communications, 2016. Vol. 37 (10): pp. 1030-1037http://hdl.handle.net/123456789/143087575 bytestext/htmlen18F-FDG-PET/CTneuroendocrine tumorsomatostatin receptor imagingtumor biologytumor heterogeneityPerformance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristicsArticle